Avantor Past Earnings Performance

Past criteria checks 1/6

Avantor has been growing earnings at an average annual rate of 52.6%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 4.7% per year. Avantor's return on equity is 4.9%, and it has net margins of 3.8%.

Key information

52.6%

Earnings growth rate

65.2%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate4.7%
Return on equity4.9%
Net Margin3.8%
Next Earnings Update26 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Avantor makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:AVG Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 246,8672601,4970
31 Dec 236,9673211,4660
30 Sep 237,0393641,4700
30 Jun 237,1764231,4750
31 Mar 237,3426101,4690
31 Dec 227,5126621,4570
30 Sep 227,6255981,4420
30 Jun 227,6035721,4450
31 Mar 227,5515341,4630
31 Dec 217,3865081,4260
30 Sep 217,2694661,4420
30 Jun 217,0402671,3880
31 Mar 216,6601691,3450
31 Dec 206,394521,3420
30 Sep 206,127711,3360
30 Jun 206,0261351,3320
31 Mar 206,079-2261,3340
31 Dec 196,040-3351,3290
30 Sep 195,990-5141,2940
30 Jun 195,981-5541,3030
31 Mar 195,926-3301,3050
31 Dec 185,864-3561,3210
30 Sep 185,120-6391,2150
31 Dec 171,247-4153760
31 Dec 16691-422570
31 Dec 15637221850

Quality Earnings: AVG has a large one-off loss of $194.4M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: AVG's current net profit margins (3.8%) are lower than last year (8.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AVG has become profitable over the past 5 years, growing earnings by 52.6% per year.

Accelerating Growth: AVG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AVG had negative earnings growth (-57.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.7%).


Return on Equity

High ROE: AVG's Return on Equity (4.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies